Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations..docx

<b>Supplementary Tables</b>. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <b>Background</b> The implication of MET alterations in solid tumors and the immune microenvironment remains elusive. <b>Materials &amp; Methods</b> FFPE samples of 21 patients with solid tumors harboring MET alterations were used for IHC staining. Extracted RNA was analyzed with the NanoString nCounter human PanCancer Immune Profiling Panel. <b>Results</b> Patients were diagnosed with lung (N=10), breast (N=5), genitourinary (N=3), or colorectal cancer (N=3). Eleven had a MET missense mutation, 4 had an exon 14 splice site mutation, and 6 had MET amplification. CD6, CCL19, ATM, CD40LG, XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed in MET-altered cancers. <b>Conclusion</b> MET alterations may have a role in various solid tumors as potential therapeutic targets and combination therapy candidates with immune checkpoint inhibitors.